Androgen Deprivation Therapy

Status: open

14-021 - [556164-14] Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment for Prostate Cancer

Contact Us Or call (251) 445-9834


RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. 

IRB Number 14-021


This trial is sponsored by Radiation Therapy Oncology Group.

Providers Associated With This Trial

Principle Investigator

  • Elesyia OutlawView Profile
    Elesyia D. Outlaw, M.D.Radiation OncologistDirector of Women's Radiotherapy Program; Program Director of Brachytherapy Program; Associate Professor of Interdisciplinary Clinical Oncology

Sub Investigators

This link will open in a new tab or window.